UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043025
Receipt number R000049117
Scientific Title Acute exacerbation of fibrosing interstitial lung disease; multicenter retrospective cohort study
Date of disclosure of the study information 2021/01/16
Last modified on 2021/01/15 23:56:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Acute exacerbation of fibrosing interstitial lung disease; multicenter retrospective cohort study

Acronym

Cohort study of acute exacerbation of fibrosing interstitial lung disease

Scientific Title

Acute exacerbation of fibrosing interstitial lung disease; multicenter retrospective cohort study

Scientific Title:Acronym

Cohort study of acute exacerbation of fibrosing interstitial lung disease

Region

Japan


Condition

Condition

Acute exacerbation of fibrosing interstitial lung disease

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the course of treatment of fibrosing interstitial lung disease.

Basic objectives2

Others

Basic objectives -Others

To improve treatment by assessing patient background and treatment progress.

Trial characteristics_1

Others

Trial characteristics_2

Others

Developmental phase

Not applicable


Assessment

Primary outcomes

To clarify the clinical course of fibrosing interstitial lung disease.

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Cases treated for acute exacerbation of fibrosing interstitial lung disease between January 2012 and December 2019.

Key exclusion criteria

Cases in which the subject himself/herself has requested the refusal of the provision of information

Target sample size

400


Research contact person

Name of lead principal investigator

1st name Daichi
Middle name
Last name Fujimoto

Organization

Wakayama Medical University

Division name

Department of Pulmonary Medicine and Medical Oncology

Zip code

641-8509

Address

811-1, Kimiidera, Wakayama City

TEL

073-441-0619

Email

daichi@wakayama-med.ac.jp


Public contact

Name of contact person

1st name Katsuyuki
Middle name
Last name Furuta

Organization

Wakayama Medical University

Division name

Department of Pulmonary Medicine and Medical Oncology

Zip code

641-8509

Address

811-1, Kimiidera, Wakayama City

TEL

073-441-0619

Homepage URL


Email

k-furuta@wakayama-med.ac.jp


Sponsor or person

Institute

Wakayama Medical University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Research Ethics Committee of Wakayama Medical University

Address

811-1 Kimiidera, Wakayama, Wakayama Prefecture

Tel

073-447-2300

Email

wa-rinri@wakayama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

神戸市立医療センター中央市民病院(兵庫県)、和歌山県立医科大学附属病院(和歌山県)


Other administrative information

Date of disclosure of the study information

2021 Year 01 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

384

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2020 Year 06 Month 16 Day

Date of IRB

2020 Year 07 Month 22 Day

Anticipated trial start date

2020 Year 07 Month 22 Day

Last follow-up date

2021 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Clarify the clinical course by assessing information before diagnosis and at the time of diagnosis of acute exacerbation (patient background, blood tests, respiratory function tests, imaging tests, reasons for exacerbation, treatment for exacerbation, outcome, etc.).


Management information

Registered date

2021 Year 01 Month 15 Day

Last modified on

2021 Year 01 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049117


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name